Genomic Profile of Breast Cancer: Cost-Effectiveness Analysis from the Spanish National Healthcare System Perspective

PUBLICATION: Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Read More

2024-03-25T11:22:23-07:00September 12th, 2014|Evidence, Healthcare Economics, MammaPrint, Other|
Read More

MammaPrint Pre-Screen Algorithm (MPA) Reduces Chemotherapy in Patients with Early-Stage Breast Cancer

PUBLICATION: S Afr Med J. 2013 Jul 3;103(8):522-6. doi: 10.7196/samj.7223. Read More

2024-03-25T10:45:11-07:00July 3rd, 2013|Adjuvant, Evidence, MammaPrint|
Read More

Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients

PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retèl Read More

2024-03-25T10:45:47-07:00June 18th, 2013|Adjuvant, Evidence, MammaPrint, MINDACT, Other|
Read More

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub Read More

2024-03-25T10:47:25-07:00June 1st, 2013|Evidence, Healthcare Economics, MammaPrint, Other|
Read More

Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Read More

2024-03-25T10:52:27-07:00June 1st, 2012|Evidence, Healthcare Economics, MammaPrint, Other|
Read More

Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode

PUBLICATION: Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb Read More

2024-03-25T10:54:31-07:00February 22nd, 2012|Evidence, Healthcare Economics, MammaPrint, Other|
Read More

Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance

PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub Read More

2024-03-25T10:55:06-07:00January 1st, 2012|Evidence, Healthcare Economics, MammaPrint, Other|
Read More

Cost-effectiveness of the 70-gene Signature Versus St. Gallen Guidelines and Adjuvant Online for Early Breast Cancer

PUBLICATION: Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Read More

2024-03-25T11:00:12-07:00May 2nd, 2010|Evidence, Healthcare Economics, MammaPrint, Other|
Read More


Agendia precision oncology

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.

Go to Top